ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $624,451 | +56.9% | 5,113 | +32.8% | 0.04% | +41.4% |
| Q3 2022 | $398,000 | +11.2% | 3,851 | 0.0% | 0.03% | +20.8% |
| Q2 2022 | $358,000 | -20.8% | 3,851 | 0.0% | 0.02% | +4.3% |
| Q1 2022 | $452,000 | +11.3% | 3,851 | +27.6% | 0.02% | -4.2% |
| Q4 2021 | $406,000 | +7.4% | 3,017 | +27.4% | 0.02% | +9.1% |
| Q3 2021 | $378,000 | +21.2% | 2,369 | 0.0% | 0.02% | +10.0% |
| Q2 2021 | $312,000 | +40.5% | 2,369 | +37.6% | 0.02% | +33.3% |
| Q1 2021 | $222,000 | -7.1% | 1,722 | +20.1% | 0.02% | -25.0% |
| Q4 2020 | $239,000 | – | 1,434 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |